Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab

Introduction PD-L1 is established as a predictive marker for therapy of non-small cell lung cancer with pembrolizumab. Furthermore, PD-L1 positive melanoma has shown more favorable outcomes when treated with anti-PD1 antibodies and dacarbazine compared to PD-L1 negative melanoma. However, the role o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cancer research and clinical oncology 2017-10, Vol.143 (10), p.1977-1984
Hauptverfasser:	Brüggemann, C., Kirchberger, M. C., Goldinger, S. M., Weide, B., Konrad, A., Erdmann, M., Schadendorf, D., Croner, R. S., Krähenbühl, L., Kähler, K. C., Hafner, C., Leisgang, W., Kiesewetter, F., Dummer, R., Schuler, G., Stürzl, M., Heinzerling, L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies B7-H1 Antigen - biosynthesis B7-H1 Antigen - genetics B7-H1 Antigen - immunology Cancer Research Case-Control Studies Chemotherapy CTLA-4 protein Dacarbazine Female Gene Expression Hematology Humans Immunohistochemistry Immunotherapy Internal Medicine Ipilimumab - administration & dosage L1 gene Male Medical prognosis Medicine Medicine & Public Health Melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - immunology Melanoma - pathology MicroRNAs Middle Aged Monoclonal antibodies Neoplasm Staging Non-small cell lung carcinoma Oncology Original Article – Cancer Research Paraffin PD-1 protein PD-L1 protein Polymerase chain reaction Predictive Value of Tests Real-Time Polymerase Chain Reaction Retrospective Studies RNA, Messenger - genetics RNA, Messenger - metabolism Skin cancer Skin Neoplasms - drug therapy Skin Neoplasms - genetics Skin Neoplasms - immunology Skin Neoplasms - pathology Standardization Statistical analysis Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!